The EMHG first published its protocol for an in vitro contracture test (IVCT) in 19841 and this has ever since formed the bedrock of clinical diagnosis and phenotyping. In 20152 the EMHG published the updated guidelines for investigation of malignant hyperthermia susceptibility. Evidently the rigour of the IVCT stood the test of time and was used in more than 10 000 individuals worldwide to define their MH risk, representing an example of preventative medicine and improved patient safety